(555h) Engineering PEO-Pdlla Nanoparticles Containing the PI3K Inhibitor LY294002
Poly(ethylene oxide)-b-poly(D,L lactic acid) (PEO-PDLLA) nanoparticles containing LY294002 loaded at > 10 wt% were fabricated using FNP with sizes ranging from ~ 150 â 250 nm and zeta potentials > -20 mV in DI water. The PEO and PDLLA molecular weights in the diblock copolymer result in PEO brush layers at the particlesâ surface and steric stabilization. This drug delivery system has sufficient LY294002 loading to provide clinically relevant LY294002 dosing and allows for the translation of LY294002 into the in vivo setting. This presentation will focus on the design, synthesis, and characterization of these nanoparticles. The flexible particle fabrication methods described here can be applied to a wide range of therapeutic agents, and the use of FNP allows for future scale-up of nanoparticle production.
- Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014;13(2):140-56. doi: 10.1038/nrd4204. PubMed PMID: WOS:000331145900018.